Cargando…

Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency

CONTEXT: Serum insulin-like growth factor 1 (IGF-1) levels are relatively constant in somatropin-treated children with growth hormone deficiency (GHD), and guide dose adjustments for clinical efficacy and long-term safety. IGF-1 levels following treatment with long-acting growth hormones such as lon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zhengning, Shu, Aimee D, Bach, Mark, Miller, Bradley S, Rogol, Alan D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668201/ https://www.ncbi.nlm.nih.gov/pubmed/34913019 http://dx.doi.org/10.1210/jendso/bvab168

Ejemplares similares

Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients
por: Miller, Bradley S, et al.
Publicado: (2022)

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
por: Thornton, Paul S, et al.
Publicado: (2021)

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial
por: Saenger, Paul, et al.
Publicado: (2022)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
por: Maniatis, Aristides K, et al.
Publicado: (2022)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin
por: Hofman, Paul, et al.
Publicado: (2023)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis
por: Yuen, Kevin C J, et al.
Publicado: (2023)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

PMON329 Survey of physician experience with once weekly somatrogon vs once daily somatropin regimen for the treatment of pediatric patients with growth hormone deficiency: results from a cross sectional, observational study
por: Gomez, Roy, et al.
Publicado: (2022)

Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study
por: Gomez, Roy, et al.
Publicado: (2023)

The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022)

Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future
por: Graber, Evan, et al.
Publicado: (2021)

Editorial: History of Growth Hormone: Animal to Human
por: Reiter, Edward O., et al.
Publicado: (2021)

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
por: Maniatis, Aristides K, et al.
Publicado: (2020)

Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations
por: Cohen, Pinchas, et al.
Publicado: (2014)

rhIGF-1 Therapy for Growth Failure and IGF-1 Deficiency in Congenital Disorder of Glycosylation Ia (PMM2 Deficiency)
por: Miller, Bradley S., et al.
Publicado: (2013)

Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
por: Horikawa, Reiko, et al.
Publicado: (2022)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

IGF1 for the diagnosis of growth hormone deficiency in children and adolescents: a reappraisal
por: Ibba, Anastasia, et al.
Publicado: (2020)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

Genes, Gender, Hormones, and Doping in Sport: A Convoluted Tale
por: Rogol, Alan D., et al.
Publicado: (2017)

Diagnostic Value of IGF-1 in Growth Hormone–Deficient Children: Is a Second Growth Hormone Stimulation Test Necessary?
por: Fatani, Tarah H
Publicado: (2023)

Significance of Direct Confirmation of Growth Hormone Insensitivity for the Diagnosis of Primary IGF-I Deficiency
por: Smyczyńska, Joanna, et al.
Publicado: (2020)

Circulating LEAP-2 Levels in Adult Growth Hormone Deficiency and Their Relationship With IGF-1
por: Vergani, Edoardo, et al.
Publicado: (2021)

SAT-LB15 24-Month Efficacy and Safety of Once Weekly and Every Other Week Administration of GX-H9, Hybrid FC-Fused Long-Acting Human Growth Hormone: A Phase 2 Study in Children With Growth Hormone Deficiency
por: Malievskiy, Oleg, et al.
Publicado: (2020)

OR21-04 Long-term Efficacy And Safety Of Once-weekly Somatrogon In Pediatric Subjects With Growth Hormone Deficiency: Results From Up To 8 Years Of Somatrogon Treatment
por: Zadik, Zvi, et al.
Publicado: (2023)

Baseline IGFBP - 3 as the Key Element to Predict Growth Response to Growth Hormone and IGF - 1 Therapy in Subjects with Non - GH Deficient Short Stature and IGF - 1 Deficiency
por: Perez-Colon, Sheila, et al.
Publicado: (2018)

THU164 Design Of The New InsiGHTS Trial: A Multicenter, Phase 2, Randomized, Open-label, Active Controlled Study To Investigate The Safety, Tolerability, And Efficacy Of Lonapegsomatropin In Prepubertal Individuals With Turner Syndrome
por: Klein, Karen O, et al.
Publicado: (2023)

Growth hormone replacement therapy in adults with growth hormone deficiency; thrice weekly low dose administration.
por: Chung, Y. S., et al.
Publicado: (1994)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mth9v2jphqme634cltt7gc3d43